Project Grant R43AI197345
Award Date 7/20/26
Completion Date 6/30/27
Dollars Obligated $314K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Dorchester, MA 02122, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Trustees of Tufts College, doing business as Tufts University School of Medicine, $862,348 on August 7, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to define the mechanisms targeting a Borrelia burgdorferi protein CspZ to prevent Lyme disease infection. The project addresses mechanisms by which B. burgdorferi evades complement-mediated immune killing. The recipient has generated a CspZ mutant...
- The National Institute of Allergy and Infectious Diseases awarded Keylicon Biosciences Inc. $314,363 on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a low-dose multivalent self-amplifying RNA (saRNA) influenza vaccine. Keylicon will engineer a saRNA construct encoding four World Health Organization-recommended influenza antigens and design modified nucleotide formulations to enhance antigen production while suppressing innate immune...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Tufts University School of Medicine a $165,000 project grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 1, 2025, with a completion date of June 30, 2027. This award funds the development of an improved transposon mutagenesis system for comprehensive genetic analysis of Borrelia burgdorferi, the causative agent of Lyme disease. The primary deliverables...
- The National Institute of Allergy and Infectious Diseases awarded the University of Toledo $768,796 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify immunoprotective antigens for preventing Lyme disease caused by Borrelia burgdorferi. The research will evaluate attenuated bacterial mutants as vaccine candidates, building on the recipient's prior identification of a BB strain lacking a chemotaxis-related gene that is rapidly cleared from...
- The National Institute of Allergy and Infectious Diseases awarded Northeastern University $100,228 on December 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of G-quadruplex DNA structures in the antigenic variation mechanism of Borrelia burgdorferi, the causative agent of Lyme disease. The research addresses the molecular mechanism by which B. burgdorferi evades host adaptive immune defenses through antigenic variation—reshaping outer...
- The National Institute of Allergy and Infectious Diseases awarded Trustees of Tufts College (doing business as Tufts University School of Medicine) $859,278 on February 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to accelerate discovery of narrow-spectrum antibiotics targeting Borrelia burgdorferi, the causative agent of Lyme disease. Narrow-spectrum agents that affect only the target bacterium avoid resistance propagation in off-target bacteria, microbiome...
- The National Institute of Allergy and Infectious Diseases awarded Bioscience Development Inc. $210,000 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to advance proteomics research on post-treatment Lyme disease syndrome (PTLDS). The recipient will conduct cerebrospinal fluid (CSF) proteome analysis using mass spectrometry to identify protein biomarkers associated with PTLDS, the chronic condition affecting 10–20 percent of Lyme disease patients...
- The Virginia Commonwealth University was awarded a $746,009 Project Grant from the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases. The grant falls under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research examining the cyclic-di-GMP signaling pathway and its role in the enzootic cycle of Lyme disease from November 18, 2022 through October 31, 2027. Specifically, the grant will fund...
- The National Institute of Allergy and Infectious Diseases awarded Yale University $503,876 on June 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate cell-intrinsic immunomodulators as molecular adjuvants for next-generation self-amplifying RNA (saRNA) vaccines. The research addresses limitations of current mRNA-LNP vaccines by developing saRNA-mediated co-expression of vaccine antigens with cell-intrinsic immunomodulators from a single RNA...
- The National Institute of Allergy and Infectious Diseases awarded the University of Kansas Medical Center Research Institute $782,462 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate mechanisms of lipoprotein sorting and secretion in Borrelia spirochetes, the causative agents of Lyme disease and relapsing fever. The research examines how Borrelia burgdorferi deploys surface lipoproteins—which cover the bacterium's unique...